Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M Duruisseaux, A Martínez-Cardús… - The Lancet …, 2018 - thelancet.com
Summary Background Anti-programmed death-1 (PD-1) treatment for advanced non-small-
cell lung cancer (NSCLC) has improved the survival of patients. However, a substantial …
被引用次数：188 相关文章

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicenter, retrospective analysis

M Duruisseaux, A Martínez Cardús… - … , vol. 6, num. 10, p. 771 …, 2018 - diposit.ub.edu
Background: Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung
cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of …

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M Duruisseaux, A Martínez-Cardús… - THE LANCET …, 2018 - iris.unito.it
Summary Background. Anti-programmed death-1 (PD-1) treatment for advanced non-small-
cell lung cancer (NSCLC) has improved the survival of patients. However, a significant …

[引用][C] Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M Duruisseaux, A Martínez-Cardús… - The Lancet …, 2018 - portalcientifico.uah.es
Background: Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung
cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of …

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicenter, retrospective analysis

M Duruisseaux, A Martínez Cardús… - 2018 - recercat.cat
Background: Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung
cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of …

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

M Duruisseaux, A Martínez-Cardús… - The Lancet …, 2018 - europepmc.org
Background Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung
cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of …

[引用][C] Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M Duruisseaux, A Martínez-Cardús… - The Lancet Respiratory …, 2018 - cir.nii.ac.jp
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a
multicentre, retrospective analysis | CiNii Research CiNii 国立情報学研究所 学術情報 …

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M Duruisseaux, A Martínez-Cardús… - The Lancet …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung
cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of …

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M Duruisseaux, A Martínez Cardús… - Lancet Respiratory …, 2018 - digibuo.uniovi.es
Summary Background. Anti-programmed death-1 (PD-1) treatment for advanced non-small-
cell lung cancer (NSCLC) has improved the survival of patients. However, a significant …

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M Duruisseaux, A Martínez-Cardús… - The Lancet Respiratory …, 2018 - Elsevier
Summary Background Anti-programmed death-1 (PD-1) treatment for advanced non-small-
cell lung cancer (NSCLC) has improved the survival of patients. However, a substantial …